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Abstract
Background: The study tested the hypothesis that apoptosis can prevent and control growth of
neoplastic cells. Previous studies in-vitro have shown that the pro-apoptotic P2X7 receptor
regulates growth of epithelial cells. The specific objective of the present study was to understand
to what degree the P2X7 system controls development and growth of skin cancer in vivo, and what
cellular and molecular mechanisms are involved in the P2X7 action.
Methods: Skin neoplasias in mice (papillomas, followed by squamous spindle-cell carcinomas)
were induced by local application of DMBA/TPA. Experiments in-vitro utilized cultured epidermal
keratinocytes generated from wild-type or from P2X7-null mice. Assays involved protein
immunostaining and Western blots; mRNA real-time qPCR; and apoptosis (evaluated in situ by
TUNEL and quantified in cultured keratinocytes as solubilized DNA or by ELISA). Changes in
cytosolic calcium or in ethidium bromide influx (P2X7 pore formation) were determined by
confocal laser microscopy.
Results: (a) Co-application on the skin of the P2X7 specific agonist BzATP inhibited formation of
DMBA/TPA-induced skin papillomas and carcinomas. At the completion of study (week 28) the
proportion of living animals with cancers in the DMBA/TPA group was 100% compared to 43% in
the DMBA/TPA+BzATP group. (b) In the normal skin BzATP affected mainly P2X7-receptor –
expressing proliferating keratinocytes, where it augmented apoptosis without evoking
inflammatory changes. (c) In BzATP-treated mice the degree of apoptosis was lesser in cancer than
in normal or papilloma keratinocytes. (d) Levels of P2X7 receptor, protein and mRNA were 4–5
fold lower in cancer tissues than in normal mouse tissues. (e) In cultured mouse keratinocytes
BzATP induced apoptosis, formation of pores in the plasma membrane, and facilitated prolonged
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BMC Cancer 2009, 9:114 http://www.biomedcentral.com/1471-2407/9/114calcium influx. (f) The BzATP-induced apoptosis, pore-formation and augmented calcium influx had
similar dose-dependence for BzATP. (g) Pore formation and the augmented calcium influx were
depended on the expression of the P2X7 receptor, while the BzATP-induced apoptosis depended
on calcium influx. (h) The BzATP-induced apoptosis could be blocked by co-treatment with
inhibitors of caspase-9 and caspase-3, but not of caspase-8.
Conclusion: (a) P2X7-dependent apoptosis is an important mechanism that controls the
development and progression of epidermal neoplasia in the mouse. (b) The P2X7-dependent
apoptosis is mediated by calcium influx via P2X7 pores, and involves the caspase-9 (mitochondrial)
pathway. (c) The diminished pro-apoptotic effect of BzATP in mouse cancer keratinocytes is
possibly the result of low expression of the P2X7 receptor. (d) Activation of P2X7-dependent
apoptosis, e.g. with BzATP could be a novel chemotherapeutic growth-preventive modality for
papillomas and epithelial cancers in vivo.
Background
The current theory of growth of epithelial cells predicts
regulation by the concerted effects of mitogenic stimuli
and apoptosis [1,2]. Apoptosis is a homeostatic process
orchestrated by the host's genome of selective cell dele-
tion without stimulating inflammatory response [3-5].
Dysregulation of apoptotic cell-death has been implicated
in states of disease and in the neoplastic transformation
[6,7]. Among the pro-apoptotic systems that operate in
epithelia [8] the P2X7 is an important mechanism because
the receptor is expressed by proliferating cells [9], and
activation of the receptor induces apoptosis that controls
directly growth of the epithelial cells [10].
The P2X7 receptor is a membrane-bound, ligand-operated
channel [11-13]. The natural ligand of the receptor is ATP
[11,12] which is present in the extracellular fluid of epi-
thelial cells at high nanomolar, low micromolar levels
[14-18]. In contrast to other types of ATP receptors, activa-
tion of the P2X7 receptor requires relatively high concen-
trations of the ligand [12]. However, studies in epithelial
cells of the female reproductive tract showed a threshold
effect and activation of P2X7-mediated apoptosis already
by nanomolar concentrations of ATP [8,18], suggesting
that ATP levels which are present in the extracellular fluid
suffice to activate the receptor.
Binding of the ligand to the P2X7 receptor can activate var-
ious cell-specific signaling cascades, including the IL-1β
[19], TNFα – TRAIL [20], and the p38, JNK/SAPK [21] and
NF-κB cascades [22]. However, a unique effect of activa-
tion of the P2X7 receptor is formation of pores in the
plasma membrane [12]. In uterine epithelial cells forma-
tion of P2X7 receptor pores induces apoptosis by a mech-
anism that involves uncontrolled influx of Ca2+ via P2X7-
pores and activation of the mitochondrial – caspase-9
pathway [13,18,23].
Until recently relatively little was known about the biolog-
ical role of the P2X7 in vivo, and particularly in the epider-
mis. Earlier studies suggested involvement of the P2X7
receptor in the inflammatory and immune processes since
the receptor is expressed in Langerhans and inflammatory
dendritic epidermal cells [24] and in cultured immature
dendritic epidermal cells [25]. Overexpression of P2X7
was found in lesional skin of psoriasis and atopic derma-
titis, where an intense P2X7 immunoreactivity was con-
fined to the cell membrane of the basal layer [26]. P2X7
may also play a role in chemokine secretion by normal
keratinocytes but available data are inconsistent. Inoue et
al [27] reported that treatment of cultured normal kerati-
nocytes with the P2X7 specific agonist 2',3'-0-(4-benzoyl-
benzoyl)-adenosine 5'-triphosphate (BzATP) increased
IL-6 release, while Pastore et al [26] described that BzATP
down-modulated chemokine secretion.
Studies also suggested a role for P2X7 in the control of epi-
dermal growth, but most studies were observational. The
P2X7 receptor is expressed in normal [28], in precancerous
epidermal tissues [29], and in skin cancer cells [26,30,31].
P2X7 receptors were detected already in 8–11 week-old
human fetal epidermis; they colocalized with caspase-3 and
with periderm cells positive for transferase-mediated dUTP
nick-end-labeling (TUNEL) [32]. Co-localization of the
P2X7 with apoptosis-related markers was also reported in
adult human epidermis [28], and recent studies reported
BzATP-induced cell death in normal and cancer keratinoc-
ytes, presumably by augmented apoptosis [29,30].
Although existing observational data suggest that the P2X7
may regulate growth of epithelial cells, no previous stud-
ies investigated experimentally the biological role of the
P2X7 receptor in vivo. The present study tested the hypoth-
esis that P2X7 controls epidermal cell growth in vivo by
apoptosis.
Methods
Experiments in mice in vivo
The experiments were approved by the Case Western
Reserve University (CWRU) Institutional Animal CarePage 2 of 20
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all experiments were done in accordance with CWRU
IACUC policy, following nationally and internationally
recognized guidelines. Experiments utilized 6–8 weeks
old wild-type FVB female mice (Charles River, Wilming-
ton, MA). The animal's dorsal skin (~3 × 5 cm) was shaved
using Oster animal clipper (Mountain Home, AR) fol-
lowed by weekly application of Nair hair remover lotion
http://www.naircare.com. Skin neoplasia in the mice were
induced by the "Two-Step" method, which involved
tumor initiation by local treatment with 7,12-dimethyl-
benz(a)anthracene (DMBA), followed by tumor promo-
tion with local treatment of 12-O-tetradecanoylphorbol-
13-acetate (TPA) [e.g. [33]].
Treatments included the application of one or more of the
following drugs, directly onto the shaved dorsal skin:
DMBA (50 μg/200 μl acetone [950 μM, 190 nmol, 3.3 μg/
cm2]); TPA (3 μg/200 μl acetone [20 μM, 4 nmol, 0.2 μg/
cm2]); BzATP (14.3 μg/200 μl of 2.3/1 vol/vol solution of
propylene-glycol [PG]/ethanol [EtOH] [100 μM, 20
nmol, 1.0 μg/cm2]); or the BzATP vehicle only (200 μl of
PG/EtOH). DMBA was applied once, while TPA and
BzATP were applied twice a week. The concentration/dose
of BzATP and frequency of treatments were chosen based
on data in cultured cells [8,23].
The First experiment (Experiment-1) included three
groups of animals: Control (no treatment, n = 13); DMBA
plus TPA (n = 15); and DMBA/TPA plus BzATP (n = 12).
Treatments with BzATP began two weeks prior to the
DMBA/TPA treatments. Endpoints were determined at 0–
12 (Papilloma Phase) and 14–28 weeks (Cancer Phase)
after DMBA. Endpoints were the incidence and prevalence
of lesions, as well as the mean lesion size in each living
animal. Biopsy of skin papilloma was done in one living
animal using mini rotary ElliptiPunch blade (HUOT,
Menomonee Falls, WI). Criteria for euthanasia (by cervi-
cal dislocation) prior to week 28 were according to Mont-
gomery guidelines [34], including animals with excessive
tumor burden, or with ulcerated lesions regardless of size
that were bleeding, necrosed, or infected. The experiment
was terminated at week 28, when all remaining living ani-
mals were euthanized. After death, representative samples
were obtained from all skin lesions as follows: From the
DMBA/TPA group 4 papillomas and 26 cancer samples;
and from the DMBA/TPA-BzATP group 2 papillomas and
12 cancer samples. All animals underwent postmortem
exam for the presence of metastases and non-epidermal
tumors (none were found).
Lesions developed at 0–12 weeks were defined papillo-
mas based on the actual histological diagnosis in one case,
the typical morphological appearance, and the extensive
experience gained by others using this model and meth-
odology [33,35]. Lesions developed at 14–28 weeks were
defined either as cancers (as diagnosed in each case at the
time of death), or as non-cancerous lesions, including
existing or involuting papillomas (diagnosed at the time
of death) or lesions that disappeared prior to death.
Experiments 2 and 3 studied the effects of BzATP in nor-
mal mice. Experiment-2 included one group of five ani-
mals. The shaved dorsal skin was divided into equal
anterior and posterior areas. Each animal was treated with
BzATP, applied locally twice a week for 4 weeks on the
anterior skin area; vehicle only was applied in parallel
twice a week for 4 weeks on the posterior skin area. At the
end of the experiment animals were euthanized and strips
were obtained from each animal from the anterior and
posterior treated dorsal skin areas.
Experiment-3 included two groups of 5 normal animals,
Control (vehicle only) and BzATP. Animals were treated
for 16 weeks, and after euthanasia strips were obtained
from each animal from the treated dorsal skin areas. In
addition, blood samples were obtained from each animal
from the retro-bulbar venous complex for plasma alanine
aminotransferase (ALT, glutamic pyruvic transaminase
[GPT]), and aspartate aminotransferase (AST, glutamic
oxalacetic transaminase [GOT]) assays.
Skin tissues from animals of Experiments 1–3 were
assayed for histology (H&E), P2X7-receptor immunoreac-
tivity, and in-situ TUNEL.
Experiments using cultured mouse keratinocytes
The experiments utilized primary cultures of epidermal
keratinocytes generated from 6–8 weeks old wild-type
C57Bl mice (Charles River, Wilmington, MA); from P2X7-
/-Pfizer mice [36], constructed by deletion of amino acids
506–532 of the C-terminus which is critical for P2X7-
mediated apoptosis [12,23]; or from P2X7-/-GSK mice,
which have a lacZ gene inserted at the beginning of exon
1, resulting knockout of the receptor, [37]. The P2X7-/-
Pfizer and P2X7-/-GSK mice were generated on the C57Bl
background.
Primary cultures of mouse keratinocytes were generated
by the collagenase-EDTA method as described [38], with
minor modifications. Ventral superficial skin areas involv-
ing the full epidermis and part of the dermis were scraped
and the cell suspension was washed by PBS and filtered
through a 40-μm cell strainer. Following repeated washes
and spinning cells were plated at a density of 1 × 105 cells
per cm2 on type-I collagen-coated filters [23] and used for
experiments after 24–48 hours.
P2X7-specific antisense oligonucleotides (ASO) and ran-
dom control oligonucleotides (RCO) were designed from
the published sequence of the mouse P2X7 gene [39]
(AJ009823) using a previously described method [40].Page 3 of 20
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the coding region of exon 13 (nt 1467–1486), and the
RCO were as follows: ASO – GGC GTA CCG CAG CAA
CGT AG; RCO – TAA GTA CTG CAG CTA CGT AC
(designed such that no cross-hybridization against the
P2X7 gene would occur). To assess the effects of the ASO
and RCO on P2X7 mRNA expression, cultured cells were
treated for 14 hours with or without 100 μM ASO or RCO.
Protein and mRNA methods
The receptor P2X7 protein in tissues cross sections was
detected by immunostaining as described [9,38]. The spe-
cificity of staining was previously shown in terms of incu-
bations in the absence or presence of the P2X7 antigen
peptide, where co-incubation with the P2X7 antigen pep-
tide blocked P2X7 immunoreactivity [9]. Immunofluores-
cence was captured in a fluorescence microscope Nikon
Eclipse 80i (Nikon, Melville, NY), and image analysis of
the immunofluorescence data was described [9,38].
Briefly, fields of interest were captured and saved in Adobe
Photoshop. Pictures were scanned using UN-SCAN-IT
software (Silk Scientific, Orem, UT) by choosing 5 repre-
sentative fields for each picture. Fields of interest were
chosen in reference to the epithelial component of the tis-
sue, as determined by switching to phase microscopy of
the same slide. Light intensity in each field was digitized,
and average pixel density for P2X7 per field was deter-
mined using the program software.
Western blotting of cell lysates using the anti-P2X7 anti-
body, and densitometry of the P2X7-specific 75 KDa band
(relative to glyceraldehyde-3-phosphate dehydrogenase,
GAPDH) were done as was previously described [23].
Total RNA was extracted by RNeasy mini kit (Qiagen,
Valencia, CA), and two-step real-time qPCR was carried
out as described [23]. The following mouse-specific prim-
ers were used: P2X7 receptor, forward 5'-TTC CAG GAA
GCA GGA GAG AA-3', reverse 5'-ATA CTT CAA CGT CGG
CTT GG-3' (annealing at 58°C, 2 min). GAPDH, forward
5'-TGT TGC CAT CAA TGA CCC C-3', reverse 5'-ATG AGT
CCT TCC ACG ATA CC-3' (annealing at 61°C, 1 min).
Relative quantification (RQ) was calculated using Applied
Biosystems SDS software (Foster City, CA) based on the
equation RQ= 2-ΔΔCt where Ct is the threshold cycle to
detect fluorescence.
Apoptosis assays
TUNEL assays in tissues cross sections were performed
using DeadEnd™ Fluorometric TUNEL System (Promega,
Madison, WI) according to the manufacturer's protocol.
For TUNEL-P2X7 co-staining, tissue cross sections were
first assayed for TUNEL, followed by P2X7 immunostain-
ing. The modified combined method resulted in only neg-
ligible cross fluorescence interference.
Apoptosis of cultured mouse keratinocytes was quantified
in terms of percent solubilized DNA [8], or by using the
commercial cell-death detection ELISA kit (Roche Applied
Science, Nutley, NJ) [23].
ALT and AST assays
ALT and AST assays used Liquid Reagent kits (Pointe Sci-
entific, Canton MI), and were performed according to the
supplier instructions.
Cytosolic Calcium (Ca2+i) and Ethidium-Bromide assays
Changes in Ca2+i in cultured cells were determined in
terms of changes in intracellular Fluo-4 fluorescence using
dynamic confocal laser scanning microscopy as was previ-
ously described [23]. Cultured mouse keratinocytes were
loaded with 5 μM Fluo-4/AM, and imaged with a Zeiss
LSM 510 inverted real-time confocal microscope [23].
Images were collected at 488 nm/505 nm (exc/emi) at
intervals of 10 to 15 seconds after treatment with 100 μM
BzATP, added to the perfusate. For ethidium bromide
influx experiments, glass-bottomed dishes cultured with
mouse keratinocytes were placed in the microscope.
Images (collected at 488 nm/505 nm [exc/emi]) were
taken before, and at intervals of 30 seconds after adding 5
μM ethidium bromide to the perfusate as described [23].
Average fluorescence intensity was quantified from col-
lated images using MetaVue softeware (Fryer Company
Inc., Huntley, IL) by subtracting the basal intensity value
[23].
DNA synthesis assay
Changes in DNA synthesis were determined in terms of
[3H]thymidine incorporation as described [10]. The radi-
oactivity (dpm/mg Protein, determined by Bio-Rad Pro-
tein Assay solution [Hercules, CA]) of triplicated samples
was determined by beta scintillation counting (Beckman
LS1801 scintillation counter).
Data Analysis
The proportion of living animals with papillomas or can-
cerous lesions in Experiment 1 was calculated at each
week throughout the study period and compared between
groups by chi-square or Fisher's exact test. Time-to-event
data were used to assess differences in the formation of
cancerous lesions and the Kaplan-Meier method (with
log-rank test) was used to compare differences between
groups. Mean number of lesions per animal was calcu-
lated at each week and compared between groups by inde-
pendent samples t-test. In addition, repeated-measure
ANOVA was used to examine the effect of time and
number of lesions between groups. Mean lesion size was
compared similarly for weeks 0–12. For weeks 14–28,
non-cancerous and cancerous lesions were categorized as
≤ 10 mm3 versus > 10 mm3 and the proportion of lesions
> 10 mm3 in living animals was compared betweenPage 4 of 20
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lesions were also categorized as ≤ 200 mm3 versus > 200
mm3. Cancer development (for weeks 14–28) and Sur-
vival rates (for weeks 0–28) were evaluated using the Kap-
lan-Meier method and compared between groups by log-
rank test. For cultured cells data, significance of differ-
ences between groups was estimated by t-test, or by one-
way or two-way ANOVA with Tukey-Kramer Multiple
Comparisons post test analysis.
Supplies
All chemicals, unless specified otherwise, were obtained
from Sigma Chemical (St. Louis, MO). Primary antibodies
for the immunostaining and Western blots were as fol-
lows: Rabbit polyclonal anti-P2X7 receptor antibody,
which recognizes the functional full length P2X7 receptor
[23] was from Alomone Laboratories (Jerusalem, Israel);
rabbit anti-GAPDH antibody was from BD Transduction
Laboratories (Lexington, KY). The secondary antibody





tone (zVAD-FMK), and Asp-Glu-Val-Asp-O-methyl-
fluoromethylketone (DEVD-FMK) were from Calbiochem
(La Jolla, CA), and were used at a concentration of 50 μM.
Results
BzATP modulates DMBA/TPA skin effects (Experiment-1)
Local administration of DMBA/TPA induced formation of
skin lesions, papillomas at weeks 5–12, and squamous
spindle-cell carcinomas afterwards (Figs. 1, 2). About one
thirds of the papillomas involuted after week 14 and the
remaining persisted either as non-cancerous papillomas,
or have transformed to cancerous lesions (Figs. 1, 2, 3, 4,
5, 6). All cancerous lesions arose from pre-existing papil-
lomas. None of the animals in the control group had
developed skin lesions (Fig. 1A).
Co-treatment with BzATP, applied locally on skin areas
exposed to DMBA/TPA altered the incidence and pattern
of skin lesions (Figs. 1, 2, 3, 4, 5, 6). To evaluate the effects
of BzATP, changes in skin lesions in the DMBA/TPA and
DMBA/TPA+BzATP groups were compared relative to the
length of treatment. Since formation of papillomas and
cancerous lesions was time-related, with a marked cut-off
at weeks 13–14 (Fig. 3A), data were analyzed separately
for weeks 0–12 and 14–28.
Proportion of animals with lesions
At weeks 0–12 the proportion of living animals with pap-
illomas tended to be lower in the DMBA/TPA+BzATP
group than in the DMBA/TPA group, and analysis of the
proportion having a papilloma separately gave a signifi-
cant (p < 0.05) difference at week 5 of treatment (Fig. 3A;
48 ± 12% versus 80 ± 10%, respectively). The proportion
of living animals with any skin lesion at weeks 14–21 was
similar in the two groups, being initially influenced by the
death of two animals with cancers in the DMBA/TPA
group at weeks 13–14 (Fig. 3A, filled circles). However,
the proportion of living animals with any skin lesion dif-
fered significantly among the groups in weeks 22–28 (Fig.
3A). During that period of time the proportion of living
animals with non-cancerous lesions (existing and involut-
ing papillomas) decreased in both groups (Fig. 3B). In
contrast, the proportion of living animals with cancerous
lesions in the DMBA/TPA group increased steadily while
in the DMBA/TPA+BzATP group it decreased over time
(Fig. 3B). For example, in week 28 the proportions of liv-
ing animals with cancerous lesions in the DMBA/TPA and
the DMBA/TPA+BzATP groups were 100% and 43 ± 9%,
respectively (Fig. 3B).
Mean number of lesions
In both groups the mean number of papillomas per living
animal increased at weeks 0–12, but the increase in the
DMBA/TPA+BzATP group tended to be smaller than in
the DMBA/TPA group (Fig. 4A). Independent samples t-
test revealed a significant difference at week 10 (2.3 ± 0.5
and 1.2 ± 0.4 papillomas per animal [mean ± SD], respec-
tively, p < 0.04). Also, repeated measures ANOVA yielded
a significant time effect (p < 0.01) for the DMBA/TPA and
DMBA/TPA+BzATP curves at weeks 0–12 (Fig. 4A). At
weeks 14–28 the mean number of total lesions per living
animal was not significantly different between the two
groups (Fig. 4A). In both groups the mean number of
non-cancerous lesions decreased over the 14–28 weeks
period (Fig. 4B), while the mean number of cancerous
lesions remained the same (Fig. 4C).
Mean lesion size
Animals in both groups were compared relative to the
total size of lesions (in mm3) per animal. In both groups
the mean total papillomas size per living animal increased
at weeks 0–12, but the increase in the DMBA/TPA+BzATP
group was smaller than in the DMBA/TPA group (Figs. 1B,
C, 5A). Independent samples t-test revealed significant
differences at all weeks for mean total papillomas size (p
< 0.01–0.03, Fig. 5A). For example, in week 12 mean total
papillomas size (in mm3) per animal was 5.8 ± 1.1 versus
3.4 ± 1.0 (mean ± SD), respectively (p < 0.01, Fig. 5A).
Likewise, repeated measures ANOVA yielded a significant
time effect (p < 0.01); a significant group effect (p < 0.02);
and a non-significant time*group interaction effect (p >
0.1), for the DMBA/TPA and DMBA/TPA+BzATP curves
(Fig. 5A). The latter analysis indicates non-interacting
trends for the two curves.
At weeks 14–28 the variability of the lesions sizes among
the two groups was large, due to the excessive growth of
some lesions unproportionally to others (e.g. Figs. 1D–I).Page 5 of 20
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among the two groups. However, since most non-cancer-
ous lesions in both groups tended to be smaller than 10
mm3 and the proportion of animals with non-cancerous
lesions of > 10 mm3 was low (< 10%) in both groups (Fig.
5B, triangles), data of the proportion of living animals
with cancerous lesions > 10 mm3 were compared among
the two groups. Figure 5B shows a significantly smaller
proportion of living animals in the DMBA/TPA+BzATP
group with cancerous lesions > 10 mm3 after week 23 than
in the DMBA/TPA group. For example, in week 28 the pro-
portion of living animals with cancerous lesions > 10
mm3 were 81% ± 8% compared to 16 ± 4% in the DMBA/
TPA and the DMBA/TPA+BzATP groups, respectively (Fig.
5B).
Interestingly, five mice in the DMBA/TPA+BzATP group
survived despite having developed relatively large cancer-
ous lesions (e.g. Fig. 1I), while maintaining normal
weight and exhibiting normal behavior. In contrast, most
mice in the DMBA/TPA group with already smaller cancer-
ous lesions (e.g. Fig. 1H) had to be euthanized per proto-
col due to poor general condition and excessive tumor
burden. Analysis of the proportion of living animals with
Representative pictures of DMBA/TPA – induced skin lesions in mice in-vivo, and the effects of co-treatment with BzATPFigure 1
Representative pictures of DMBA/TPA – induced skin lesions in mice in-vivo, and the effects of co-treatment 
with BzATP. Arrows in D and E point to involuting papillomas.Page 6 of 20
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higher proportion of animals in the DMBA/TPA+BzATP
group than in the DMBA/TPA group (Fig. 5C), but the dif-
ferences did not reach statistical significance.
Summary of the trends of cancer development and survival rates
Using time-to-event data analysis it was found that devel-
opment of cancerous lesions was significantly slower and
lower in the DMBA/TPA+BzATP group than in the DMBA/
TPA group (Fig. 6A).
Survival curves for the DMBA/TPA and DMBA/
TPA+BzATP groups were generated based on event (death
from cancer) and time-to-event (in weeks) for each group.
Log-rank test was used to compare the survival curves
based on group. The overall survival rates among the two
groups did not differ statistically, although there was a
tendency of earlier deaths in the DMBA/TPA group com-
pared to the DMBA/TPA+BzATP group (Fig. 6B).
Animals' weights
There were no significant differences in animals' weights
among the control or the DMBA/TPA and DMBA/
TPA+BzATP treatment groups over the course of 28 weeks
(not shown).
Morphological and histological skin changes
There were no significant differences in the morphological
(Figs. 1A–I) and histological characteristics (Figs. 2A, B) of
the unaffected normal skin in the DMBA/TPA and the
DMBA/TPA+BzATP groups. Similarly there were no signif-
icant differences in the morphological (Figs. 1B–E) and
histological characteristics of papillomas in the DMBA/
TPA and DMBA/TPA+BzATP groups (Figs. 2C, D). In both
groups after week 14 some papillomas remained intact
while other started to involute (Figs. 1D, E, 2E). However,
in both groups most papillomas (about two third) under-
went cancerous transformation to squamous cell carcino-
mas with spindle-cell changes (Figs. 2F–I). There were no
significant changes in the morphological (Figs. 1F–I) and
histological characteristics (not shown) of cancers in the
two groups.
P2X7 receptor expression is lower in mouse skin cancer 
tissues
Cellular effects of BzATP are mediated mainly by the P2X7
receptor [11,12]. The present data showed that mouse
normal, papilloma, and cancer skin cells express the P2X7
receptor, but levels of the receptor in cancer tissues were
significantly lower than in normal skin or papilloma tis-
sues (Fig. 7). Immunostaining with the anti P2X7 receptor
antibody of tissue cross sections containing normal skin
revealed intense immunoreactivity that localized predom-
inantly in the epidermis within proliferating keratinocytes
and epidermal hair shafts (Figs. 7A, B). In papillomas,
P2X7 immunoreactivity was intense (Fig. 7C), similar to
normal tissues (Fig. 7A), and it localized predominantly
within proliferating keratinocytes at the base of the devel-
Representative cross-sections, evaluated histologically by H&E, of DMBA/TPA – induced skin lesions in mice in-vivo, and the effects of co-treatment with BzATPFigure 2
Representative cross-sections, evaluated histologically by H&E, of DMBA/TPA – induced skin lesions in mice 
in-vivo, and the effects of co-treatment with BzATP.Page 7 of 20
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noreactivity in cancer tissues was significantly lesser than
in normal epidermal or papilloma tissues (Figs. 7E, F),
and data analysis of the P2X7 immunostaining revealed a
four fold lesser P2X7 immunoreactivity in cancer than in
normal tissues (Fig. 7G).
The immunostaining data were confirmed by Western
blot experiments. Assays of the P2X7-specific 75 KDa band
revealed a five fold lower density in cancer tissues than in
normal tissues (Fig. 7H). Further confirmation was
obtained by P2X7 mRNA experiments where qPCR assays
revealed a five fold lower P2X7 mRNA/GAPDH mRNA lev-
els in normal tissues than in cancer tissues (Fig. 7I). Col-
lectively, the data in Fig. 7 indicate that P2X7 receptor
expression levels in mouse skin cancer tissues are four-five
fold lower than in mouse normal skin tissues.
BzATP augments apoptosis in the normal skin 
(Experiments 2 and 3)
To better understand the cellular effects of BzATP in vivo,
experiments investigated the effects of BzATP in the nor-
mal mouse on skin morphology and histology; on the
immunoreactivities with the P2X7 antibody; and on apop-
tosis.
In animals of Experiment-2, BzATP was applied twice
weekly for 4 weeks on the anterior region of the shaved
dorsal skin and each animal served as its own control by
having vehicle-containing solution applied twice weekly
for 4 weeks on the posterior region of the shaved dorsal
skin (Fig. 8A). Treatments with BzATP or the vehicle solu-
tion had no visible morphological effect on the skin (Fig.
8A), and histological evaluation showed no differences in
cross sections obtained from the BzATP-treated or control
skin areas (Figs. 8B, C).
Experiment-2 also studied the effects of local treatment
with BzATP on skin apoptosis in vivo by TUNEL staining.
The negative control experiment showed minimal auto-
fluorescence in cross sections of the mouse skin (Figs. 8D,
E). In skin cross sections of non-treated mice, only faint
TUNEL staining decorated the epidermis (Fig. 8F). In con-
trast, in skin cross sections of BzATP-treated mice numer-
ous epidermal basal/parabasal cells and epidermal hair
shaft cells stained TUNEL positive (Fig. 8G). Additionally,
DAPI stains of cross sections of BzATP-treated skin
revealed greater proportion of nuclei at advanced stages of
condensation, fragmentation and pyknosis (Fig. 8I) com-
pared to controls (Fig. 8H).
In animals of Experiment-3, BzATP was applied twice
weekly for 16 weeks on the entire shaved dorsal skin. The
control group included mice that were treated only with the
vehicle. Similar to Experiment-2, treatment with BzATP had
no significant effect on skin morphology (Figs. 9A, C) and
histology (Figs. 9B, D), compared to treatment with the
vehicle only. Also, treatment with BzATP had no significant
effect on P2X7 immunoreactivity (Figs. 9E, F). However,
treatment with BzATP increased the number of TUNEL
stained epidermal basal/parabasal and hair shaft cells (Figs.
9G, H), similar to the result in Experiment-2. P2X7-TUNEL
co-staining showed that the increased TUNEL staining co-
localized with P2X7 immunoreactivity (Figs. 9I, J [low mag-
nification], Figs. 3K, L [higher magnification]).
Collectively, the data in Fig. 9 indicate that treatment with
BzATP, applied locally twice a week on the shaved dorsal
skin of normal mice, up-regulated apoptosis of proliferat-
ing epidermal and hair shaft keratinocytes. However, in
the normal mouse skin the BzATP treatment and the aug-
mented apoptosis did not affect morphology or histology
of the skin.
Summary of the effects of local treatments with DMBA/TPA (black symbols) or DMBA/TPA+BzATP (white symbols) on the proportion f living mice wi h skin lesions (Experiment-1)Figu e 3
Summary of the effects of local treatments with 
DMBA/TPA (black symbols) or DMBA/TPA+BzATP 
(white symbols) on the proportion of living mice with 
skin lesions (Experiment-1). In A, skin lesions at 0–12 
weeks of treatment were papillomas. In A and B, skin lesions 
at 14–28 weeks of treatment were grouped either as cancer-
ous lesions (squamous spindle-cell carcinomas, circles), or as 
non-cancerous lesions (existing or involuting papillomas, tri-
angles). Values in A and B are means; standard deviation 
(SD) ranged 3–11%.Page 8 of 20
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16 weeks (Experiment-3) had no significant effects on the
behavior of the animals, on their feeding habits, or on
their body weight (not shown). In addition, in animals of
Experiment-3 mean ALT and AST plasma levels were sim-
ilar among the BzATP and control groups, and were in the
normal range for the mouse (not shown).
Effects of BzATP on P2X7 expression and TUNEL in 
papilloma and cancer tissues
P2X7 immunoreactivities in cross sections of papillomas
did not differ in intensity among specimens obtained
from DMBA/TPA- or DMBA/TPA+BzATP – treated mice
(Figs. 10A, B). The intensity of P2X7 immunoreactivity in
cross sections of skin cancers was significantly weaker
Summary of the effects of local treatments with DMBA/TPA (black symbols) or DMBA/TPA+BzATP (white symbols) on the mean number of skin lesions per living animal (Experiment-1)Figure 4
Summary of the effects of local treatments with DMBA/TPA (black symbols) or DMBA/TPA+BzATP (white 
symbols) on the mean number of skin lesions per living animal (Experiment-1). Definitions of lesions were as in Fig. 
4. Values in A-C are means; SD ranged 5–9%.
Summary of the effects of local treatments with DMBA/TPA (black symbols) or DMBA/TPA+BzATP (white symbols) on the mean lesion size at 0–12 weeks of treatment (A); and on the proportion of living mice with total lesions volume per animal of > 10 mm3 (B) or > 200 mm3 (C) (Experi e t-1)Figure 5
Summary of the effects of local treatments with DMBA/TPA (black symbols) or DMBA/TPA+BzATP (white 
symbols) on the mean lesion size at 0–12 weeks of treatment (A); and on the proportion of living mice with 
total lesions volume per animal of > 10 mm3 (B) or > 200 mm3 (C) (Experiment-1). Definitions of lesions were as in 
Fig. 3. Values in A-C are means; SD ranged 2–18%.Page 9 of 20
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10A, B), but it did not differ among the DMBA/TPA and
DMBA/TPA+BzATP groups (Figs. 10E, F).
TUNEL staining was weak in cross sections of papillomas
(Fig. 10C) and cancer tissues (Fig. 10G) from the DMBA/
TPA group, similar to findings in cross sections of normal
skin (Figs. 8F, 9G). In contrast, TUNEL staining was more
intense in cross sections of papillomas (Fig. 10D) and
cancer tissues (Fig. 10H) from the DMBA/TPA+BzATP
group. In papillomas obtained from mice of the DMBA/
TPA+BzATP group, enhanced TUNEL staining decorated
basal/parabasal layers of keratinocytes outgrowing at the
base of the developing papilloma (Fig. 10D).
Mechanism of BzATP-augmented apoptosis in mouse 
keratinocytes
Dependence of BzATP-augmented apoptosis on the expression of 
the P2X7 receptor
To better understand the mechanism of BzATP pro-apop-
totic skin effects, experiments utilized cultured primary
mouse keratinocytes that were obtained from wild-type
mice, and from the P2X7-receptor – deficient P2X7-/-Pf
and P2X7-/-GSK mice.
In wild-type mouse keratinocytes BzATP augmented
apoptosis in a dose-related manner; effects began at
BzATP levels as low as 50 nM, reaching maximal effect at
100–250 μM with an estimated BzATP EC50 of about 10μM (Fig. 11A).
Pre-treatment with P2X7-receptor anti-sense oligonucle-
otide decreased expression of the P2X7-receptor (Fig. 11B,
insert); it also inhibited baseline apoptosis (which most
likely is induced paracrinologically by ATP secreted by the
cells [8]), and blocked the pro-apoptotic effect of BzATP
(Fig. 11B). Pre-treatment with random-control oligonu-
cleotides had no effect on P2X7-receptor expression (Fig.
11B, insert), or on baseline apoptosis and the apoptosis
induced by BzATP (Fig. 11B).
The dependence of the pro-apoptotic effect of BzATP on
the expression of the P2X7 receptor was further demon-
strated in experiments using keratinocytes obtained from
P2X7-receptor – deficient mice. Compared to wild-type
mouse keratinocytes, in both the P2X7-/-Pf and P2X7-/-
GSK keratinocytes treatment with 100 μM BzATP failed to
induce apoptosis (Fig. 11C).
Formation of P2X7 pores
In uterine epithelial cells [23], as well as in other types of
cells [11-13], P2X7-receptor – dependent apoptosis
involves agonist-induced acute calcium influx via P2X7
pores. To understand whether BzATP-induced apoptosis
in mouse keratinocytes involves formation of P2X7 pores,
experiments compared activation by BzATP of the P2X7
receptor (in terms of BzATP-induced increase in cytosolic
calcium [23]), and the formation of P2X7 pores (in terms
of BzATP-induced increase in the influx of ethidium bro-
mide [23]).
In mouse wild-type keratinocytes treatment with 100 μM
BzATP induced acute increase in cytosolic calcium, which
lasted at least 6 min (Fig. 12A). In cells bathed in low cal-
cium BzATP induced only spiked increase in cytosolic cal-
cium, while the prolonged sustained increase in cytosolic
calcium was abolished (Fig. 12A). The spiked, short-term
increase in cytosolic calcium most likely represents cal-
cium release from intracellular stores [8]. The lack of pro-
longed increase in cytosolic calcium in cells bathed in
extracellular medium low in calcium indicates that the
BzATP-induced prolonged increase in cytosolic calcium
involves calcium influx.
Experiments using mouse wild-type keratinocytes also
revealed that treatment with BzATP induced an acute
increase in the influx of ethidium bromide (Fig. 12B) with
a time-course similar to the increase in cytosolic calcium
(Figs. 12A, B). Both effects had similar dose-dependence
for BzATP (Fig. 12C), and they resembled the dose-
dependence of apoptosis on BzATP with threshold effects
at 50–100 nM and pre-maximal responses at 100–250 μM
(Figs. 11A, 12C).
BzATP-induced increases in cytosolic calcium and influx of ethidium 
bromide depend on the expression of the P2X7 receptor
Similar to the effects of BzATP on apoptosis, pre-treat-
ment with the P2X7-receptor anti-sense oligonucleotide
blocked the BzATP-induced increase in cytosolic calcium
Summary of the effects of local treatments with DMBA/TPA (black symbols) or DMBA/TPA+BzATP (white symbols) on the time-t -ev nt of cancer state ( ) and on the animals' sur-viv l r tes (B) (Exp riment-1)Figu e 6
Summary of the effects of local treatments with 
DMBA/TPA (black symbols) or DMBA/TPA+BzATP 
(white symbols) on the time-to-event of cancer state 
(A) and on the animals' survival rates (B) (Experi-
ment-1). Definitions of lesions were as in Fig. 3.Page 10 of 20
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P2X7 immunoreactivity in mouse normal skin (A), papilloma (C), and skin cancer tissues (E) (Experiment-1); B, D, F are parallel cross sections, respectively, stained by H&EFigure 7
P2X7 immunoreactivity in mouse normal skin (A), papilloma (C), and skin cancer tissues (E) (Experiment-1); 
B, D, F are parallel cross sections, respectively, stained by H&E. G. Analysis of P2X7 immunoreactivity compared 
among paired histologically normal and cancerous tissues. Bars are means (± SD) of levels in tissues of five mice. H. P2X7 pro-
tein assays in mouse normal and cancer skin tissues. Lysates fractionated by gel electrophoresis were immunoblotted with the 
anti P2X7 antibody and membranes were reprobed with the anti GAPDH antibody. Insert in H shows Western immunoblot of 
lysates of histologically normal and cancerous tissues obtained from the same animal. Similar results were obtained in tissues of 
two additional mice. Bars show means (± SD) of densitometry results of the P2X7-specific 75 KDa bands in tissues of three 
mice. I. P2X7 mRNA levels (relative to GAPDH mRNA) (means ± SD) in histologically normal and cancerous tissues obtained 
from three animals. In G-I data in the normal tissues were normalized in each case to an arbitrary value of 10. * – p < 0.01. AU 
– arbitrary units.
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Effects in mice in-vivo of local treatment with BzATP on skin apoptosis (Experiment-2)Figure 8
Effects in mice in-vivo of local treatment with BzATP on skin apoptosis (Experiment-2). A. Mice (n = 5) were 
treated with BzATP, applied locally twice a week for 4 weeks on the shaved anterior skin area, and with the vehicle (Control) 
applied in parallel on the shaved posterior skin area. The horizontal line shows schematically separation of the anterior and 
posterior dorsal skin regions. At the end of the experiment animals were euthanized and skin cross sections were generated 
from each animal from the anterior (B, BzATP) and posterior (C, Control) dorsal skin areas for H&E (B, C), TUNEL (D-G), 
and DAPI (H, I) staining. D-G: TUNEL staining of BzATP-treated skin tissues (E, G) and of Control skin tissues (D, F), proc-
essed in the absence (D, E) or the presence (F, G) of the TUNEL active reagent TdT (Promega). Arrows in G show enhanced 
TUNEL staining in epidermal cells of the basal/parabasal layers (horizontal arrow) and of epidermal hair shaft cells (vertical 
arrow). H, I: DAPI (nuclear) staining. Arrows in I point to nuclei of epidermal cells in basal/parabasal regions of the epidermis 
at advanced stages of condensation, fragmentation and pyknosis. Data in A-I are representative of similar results in five animals.
BMC Cancer 2009, 9:114 http://www.biomedcentral.com/1471-2407/9/114(Fig. 13A) and the BzATP-induced increase in ethidium
bromide (Fig. 13B). Pre-treatment with the random-con-
trol oligonucleotides had no effect on the responses to
BzATP (Fig. 13).
The BzATP-augmented apoptosis depends on extracellular calcium
In mouse wild-type keratinocytes lowering extracellular
calcium attenuated baseline apoptosis and blocked the
BzATP-induced apoptosis in a dose-related manner (Fig.
14A).
The BzATP-augmented apoptosis involves caspase-9 and caspase-3
Treatment of mouse wild-type keratinocytes with the cas-
pase-9 inhibitor LEHD-FMK blocked BzATP-induced
apoptosis while the caspase-8 inhibitor IETD-FMK did not
have a significant effect (Fig. 14B). The positive controls
were DEVD-FMK (specific inhibitor of the terminal cas-
pase-3) and zVAD-FMK (non-specific pan-caspase inhibi-
tor) which similarly blocked the BzATP-induced
apoptosis (Fig. 14B).
Treatment with BzATP did not induce cell proliferation
To determine if the development of the large cancerous
lesions in some animals in the DMBA/TPA+BzATP group
was the result of a pro-mitogenic effect of BzATP, rates of
DNA synthesis (in terms of [3H]thymidine incorporation)
in response to BzATP were measured in mouse wild-type
normal keratinocytes. Pre-treatments with the P2X7-recep-
Effects in mice in-vivo of local treatment with BzATP on skin apop osis (Experiment-3)Figure 9
Effects in mice in-vivo of local treatment with BzATP 
on skin apoptosis (Experiment-3). Animals (n = 5) were 
treated for 16 weeks either with BzATP, applied locally twice 
a week on the shaved dorsal skin (A, B) or with the vehicle 
(Control, n = 5, C, D). At the end of the experiment animals 
were euthanized and strips were obtained from each animal 
dorsal skin areas for H&E (B, D) and P2X7/TUNEL co-stain-
ing (E-L). Arrows in J show increased TUNEL staining co-
localizing with P2X7 immunoreactivity in epidermal cells of 
the basal/parabasal layers (horizontal arrow) and of epider-
mal hair shaft cells (vertical arrow). Assays were repeated 3–
5 times with similar trends.
Effects of treatments with BzATP on P2X7 expression and apop osis in DMBA/TPA – induced skin papilloma  (A-D) and can ers (E-H) (Experiment-1)Figure 10
Effects of treatments with BzATP on P2X7 expres-
sion and apoptosis in DMBA/TPA – induced skin pap-
illomas (A-D) and cancers (E-H) (Experiment-1). 
Assays were repeated 4 times with similar trends. C, D, G, 
H are parallel cross sections to A, B, E, F, respectively.Page 13 of 20
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trol oligonucleotides, and treatments with BzATP had no
significant effect on [3H]thymidine incorporation (Fig.
15).
Discussion
The main finding of the study was that pharmacological
activation of P2X7-mediated apoptosis, by local skin
application of the P2X7-receptor agonist BzATP, inhibited
DMBA/TPA-induced formation of skin papillomas and
squamous spindle-cell carcinomas. Since the main cellu-
lar effect of BzATP was augmentation of apoptosis, this
discovery provides the first direct support for the hypoth-
esis that apoptosis is an important mechanism in vivo
which controls the development and progression of neo-
plasia. The present findings also support the hypothesis
that P2X7 is an important physiological pro-apoptotic sys-
tem in epithelia, particularly those derived from the ecto-
derm (skin and breast), the uro-genital sinus (bladder),
and the distal paramesonephric duct (uterine cervix and
endometrium) [9,38,41], and Li, Qi, Zhou, Fu, Abdul-
Karim, MacLennan, and Gorodeski GI: P2X7 receptor
expression is decreased in epithelial cancer cells of ecto-
dermal, uro-genital sinus, and distal paramesonephric-
duct origin (submitted, 2009).
Co-treatment with BzATP delayed formation of DMBA/
TPA-induced papillomas, and resulted in fewer and
smaller papillomas. Some papillomas regressed and invo-
luted spontaneously, as was previously described [35],
and the effect was unrelated to the treatment with BzATP.
However, the majority (about two thirds) either pro-
gressed into squamous spindle-cell carcinomas or per-
sisted as non-cancerous lesions. The latter trends
depended on whether animals were co-treated with
BzATP; thus, in mice co-treated with BzATP the propor-
tion of animals with cancers at week 14 was lower than in
the DMBA/TPA+BzATP group (50% versus 80%) and
remained relatively stable, while in the DMBA/TPA group
the proportion of animals with cancers increased steadily,
reaching 100% at week 24. These data suggest that local
treatment with BzATP inhibits formation of DMBA/TPA-
induced skin papilloma, and it can also inhibit papilloma
transformation into cancers.
BzATP had little effect on the number of cancerous lesions
per animal at weeks 14–28, and on the proportion of ani-
mals with cancerous lesions > 10 mm3 at weeks 14–22. In
contrast, after week 23 the proportion of living animals
with cancerous lesions > 10 mm3 increased in the DMBA/
TPA group while it had decreased in the DMBA/
TPA+BzATP group. These data suggest that local treatment
with BzATP exerts an inhibitory effect on the development
on skin neoplasia. Interestingly, at weeks 15–24, among
animals with cancerous lesions, the proportion of living
animals with lesions larger than 200 mm3 tended to be
Effects of BzATP on apoptosis in cultured mouse keratinoc-ytesFigure 11
Effects of BzATP on apoptosis in cultured mouse 
keratinocytes. In all experiments levels of apoptosis were 
normalized to an arbitrary value of 2 in control cells. AU – 
arbitrary units. A. BzATP dose-response effect in cultured 
mouse normal (wild-type, C57Bl) keratinocytes (means ± 
SD, n = 3). Cells were treated with one of the indicated con-
centrations of BzATP for 8 hours. B. Cultured mouse normal 
keratinocytes (wild-type, C57Bl) were pre-treated with 100 
μM anti-sense P2X7 oligonucleotides (ASO) or random-con-
trol P2X7 oligonucleotides (RCO) for 14 hours followed by 8 
hours treatment with 100 μM BzATP. Control – cells treated 
with the vehicle of the ASO. Values are means (± SD) of 3 
experiments for each condition. Insert in B is Western 
immunoblot with anti-P2X7 antibody of lysates of cells 
treated with ASO or RCO (n = 2). C. BzATP time-response 
effect in cultured mouse normal keratinocytes (wild-type, 
C57Bl; filled triangles), or in keratinocytes obtained from 
P2X7-deficient (P2X7-/-Pfizer [empty circles] or P2X7-/-GSK 
[filled circles]) mice (both in the C57Bl background). Values 
are means (± SD) of 3 experiments for each condition. 
Changes in apoptosis in A and B were determined in terms 
of solubilized DNA; changes in apoptosis in C were deter-
mined using cell-death detection ELISA.Page 14 of 20
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BMC Cancer 2009, 9:114 http://www.biomedcentral.com/1471-2407/9/114higher in the DMBA/TPA+BzATP group than in the
DMBA/TPA group. This effect cannot be explained by aug-
mented proliferation since BzATP did not stimulate DNA
synthesis in cultured normal keratinocytes. Instead, the
effect could be explained by comparing the survival curves
(Fig. 6B) and the proportions of animals with smaller and
larger size cancerous lesions (Figs. 5B, C). Thus, cancer-
Effects of BzATP in mouse wild-type normal keratinocytes on increases in cytosolic calcium (above baseline, ΔCa2+i), in medium containing 1.2 mM Ca2+ or 1.2 mM Ca2+ plus 1.2 mMGTA (A, C); and on the nflux of thidium brom de (E h-Br,B, C)Figure 12
Effects of BzATP in mouse wild-type normal kerati-
nocytes on increases in cytosolic calcium (above 
baseline, ΔCa2+i), in medium containing 1.2 mM Ca2+ 
or 1.2 mM Ca2+ plus 1.2 mM EGTA (A, C); and on the 
influx of ethidium bromide (Eth-Br, B, C). Ca2+o: extra-
cellular calcium. In A and B BzATP was added (arrows) at 
100 μM. In C cells were treated with one of the indicated 
concentrations of BzATP for 8 hours. Levels of ΔCa2+i 
(empty circles) were determined 2 min after adding BzATP; 
changes in Eth-Br fluorescence (filled circles) were deter-
mined 5 min after adding BzATP. Values in C are means (± 
SD). Experiments were repeated 3 times. AU – arbitrary 
units.
Effects of anti-sense P2X7 oligonucleotides on BzATP-induced increa  in cytosolic calcium (ΔCa2+i, A) and on the l x of ethidium bromide (Eth-Br, B)Fig re 13
Effects of anti-sense P2X7 oligonucleotides on 
BzATP-induced increase in cytosolic calcium (ΔCa2+i, 
A) and on the influx of ethidium bromide (Eth-Br, B). 
Cultured mouse wild-type normal keratinocytes were pre-
treated with 100 μM anti-sense P2X7 oligonucleotides (ASO) 
or random-control P2X7 oligonucleotides (RCO) for 14 
hours followed by 8 hours treatment with 100 μM BzATP. 
Control – cells treated with the vehicle of the ASO. Levels of 
ΔCa2+i (A) and of Eth-Br fluorescence (B) were determined 
as in Fig. 12. The experiments were repeated twice with sim-
ilar trends.Page 15 of 20
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more often with smaller lesions while cancer-related
deaths in the DMBA/TPA+BzATP group were associated
with relatively larger lesions. This suggests that treatment
with BzATP also prolonged the life of animals with devel-
oped cancers.
The data showed that the main targets of BzATP in the
normal skin are proliferating keratinocytes of the epider-
mal basal/parabasal layers and hair shafts. In these P2X7-
receptor – expressing cells BzATP augmented apoptosis
without evoking inflammatory changes that potentially
could have been induced by activation of the P2X7 recep-
tor [11,12]. Experiments in P2X7-deficient normal kerati-
nocytes and in normal keratinocytes treated with anti-
sense P2X7 oligonucleotides showed that the P2X7 recep-
tor is a necessary mediator of the pro-apoptotic effect of
BzATP, suggesting that the effect of BzATP is mediated by
augmentation of P2X7-mediated apoptosis.
Similar to the normal skin, the main targets of BzATP in
papilloma tissues were P2X7-receptor expressing prolifer-
ating keratinocytes at the base of developing papillomas.
The importance of this finding relates to the fact that in
the mouse DMBA/TPA model, papillomas at risk for
developing into cancer are characterized by rapidly prolif-
A. Dependence of the BzATP-induced apoptosis on extracel-lular calcium (Ca2+o)Figure 14
A. Dependence of the BzATP-induced apoptosis on 
extracellular calcium (Ca2+o). Cultured mouse wild-type 
normal keratinocytes were shifted for 10 minutes to medium 
containing one of the indicated Ca2+o concentrations. Con-
trol (physiological) level of Ca2+o was 1.2 mM, and levels of 
Ca2+o were modulated by adding EGTA. Cells were treated 
with 100 μM BzATP (or the vehicle, Control), and changes in 
apoptosis were determined after 8 hours. B. Modulation of 
BzATP-induced apoptosis (100 μM, 8 hours) in mouse wild-
type normal keratinocytes by caspase inhibitors (each added 
at 50 μM for 8 hours). In A and B changes in apoptosis were 
determined in terms of solubilized DNA. Values are means 
(± SD) of 3 experiments. Levels of apoptosis were normal-
ized to an arbitrary value of 2 in non-treated cells. AU – arbi-
trary units. In A, * – p < 0.01 compared to Ca2+o 1.2 mM. In 
B, * – p < 0.01 compared to control.
Effects of pre-treatment with anti-sense P2X7 oligonucle-otides (ASO) or random-control P2X7 oligonuc e tides (RCO) (both at 100 μM for 14 hours), and of tr atm nts with Bz TP (100 μM, 8 h urs) on [3H]thymidine incorpora-tion in mouse wild-type n m l keratin cytes (values aremean ± D, n = 4)Figure 15
Effects of pre-treatment with anti-sense P2X7 oligo-
nucleotides (ASO) or random-control P2X7 oligonu-
cleotides (RCO) (both at 100 μM for 14 hours), and of 
treatments with BzATP (100 μM, 8 hours) on 
[3H]thymidine incorporation in mouse wild-type nor-
mal keratinocytes (values are means ± SD, n = 4).Page 16 of 20
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the papilloma [35]. Since treatment with BzATP decreased
the incidence of DMBA/TPA-induced papillomas and
their transformation into cancer, it is likely that the cellu-
lar mechanism of BzATP action involved augmented
apoptosis of proliferating papilloma keratinocytes bear-
ing the potential of malignant transformation.
One of the differences between BzATP effects in the nor-
mal skin and in papilloma tissues was the lack of macro-
scopic effects in the former, while inhibiting the
development and growth of papillomas. Thus, treatment
with BzATP for 16 weeks in normal mice augmented
apoptosis of proliferating keratinocytes but it did not pro-
duce thinning or ulceration of the skin, as would be
expected of a potent pro-apoptotic drug. Similarly, there
were no significant differences in the morphological and
histological characteristics of the unaffected normal skin
between animals in the DMBA/TPA+BzATP group (BzATP
treatment for 30 weeks) and the DMBA/TPA group. How-
ever, in the DMBA/TPA+BzATP group the enhanced apop-
tosis was associated with inhibition of papilloma
development. The disparity between BzATP effects in nor-
mal and papilloma tissues could be related to differences
in the growth rate of the respective keratinocytes. Normal
skin cells are slow growing and their overall growth rate is
apparently not affected by BzATP; in contrast, in the fast
growing papilloma keratinocytes BzATP-induced apopto-
sis slows and inhibits growth.
The data in normal mice also showed that local treatment
with BzATP had no adverse systemic effects, suggesting a
relatively safe profile for the drug when applied locally on
the skin. These data indicate that BzATP is absorbed from
the skin into the basal/parabasal epidermal regions and
hair shafts. The data also suggest that the predominant
effect of BzATP is induction of apoptosis at the site of
application, targeting rapidly growing proliferating kerat-
inocytes.
In contrast to papillomas, the expression level of P2X7
receptors in DMBA/TPA-induced cancer cells was low, as
was evident by three assays: in-situ immunoreactivity,
Western blots, and qPCR. These findings are similar to
those reported in non-melanoma skin cancer cells [30]
and in uterine, bladder and breast epithelial cancers
[9,38,41], and Li, Qi, Zhou, Fu, Abdul-Karim, MacLen-
nan, and Gorodeski GI: P2X7 receptor expression is
decreased in epithelial cancer cells of ectodermal, uro-
genital sinus, and distal paramesonephric-duct origin
(submitted, 2009). The findings suggest that the rapid
proliferation of cancer cells could be in part due to the low
expression of the P2X7 receptor and to attenuated P2X7-
mediated apoptosis. Treatment with BzATP augmented
apoptosis even in cancer cells expressing low levels of the
receptor, but the effect was smaller than in normal or pap-
illoma cells. The significance of this effect is at present
unclear although it could have modified the biological
behavior of the cancers and have contributed to the pro-
longation of life in the affected animals, as was discussed
above.
Until recently little was known about the mechanisms of
P2X7-receptor – apoptosis in the skin, and one of the
objectives of the present study was to begin to understand
the signaling pathways and molecular mechanisms that
are involved in BzATP action in keratinocytes. The data
suggest that, similar to uterine epithelial cells [8,18], the
P2X7-receptor – apoptosis in keratinocytes depends on
enhanced calcium influx via P2X7 pores, and is mediated
by the caspase-9 – mitochondrial pathway. The following
experimental findings in the present study support this
hypothesis: (a) Treatment with BzATP induced formation
of pores and enhanced calcium influx; (b) the BzATP-
induced apoptosis, pore formation and the augmented
and prolonged calcium influx were critically dependent
on the expression of the P2X7 receptor; (c) the BzATP-
induced apoptosis, pore formation and the augmented
calcium influx had similar dose-dependence on BzATP;
(d) the BzATP-induced pore formation and the aug-
mented calcium influx began shortly (30–60 seconds)
after adding BzATP. In contrast, the BzATP-induced apop-
tosis required hours of treatment with BzATP, commensu-
rate with a gene-mediated effect; (e) the BzATP-induced
apoptosis depended on the presence of extracellular cal-
cium at a physiological concentration of 1.2 mM, and on
calcium influx; (f) the BzATP-induced apoptosis could be
blocked by co-treatment with inhibitors of caspase-9 and
caspase-3, but not of caspase-8. Since caspase-3 is a termi-
nal step in the caspase cascade [5,6], a possible interpreta-
tion of the present results is that P2X7-receptor –
apoptosis is mediated by the caspase-9 (mitochondrial)
pathway. Collectively the data in mouse keratinocytes
suggest that BzATP-dependent activation of the P2X7
receptor involves formation of pores in the plasma mem-
brane, and that facilitated uncontrolled influx of Ca2+ via
the P2X7 pores stimulates apoptosis by the mitochondrial
– caspase-9 pathway.
P2X7 pores are believed to be formed of channels com-
posed of pannexins [42,43] and ectodomains of the P2X7
molecule [23,42]. However, the ability of agonists to
induce apoptosis via the P2X7 pore mechanism is deter-
mined primarily by the cellular expression of the P2X7
receptor [13,23]. The present study showed that papil-
loma keratinocytes express the P2X7 receptor; therefore,
the high expression levels of the receptor in papilloma
cells and the significant apoptotic effects in response to
BzATP could explain the inhibitory effect of BzATP on
papilloma development. In contrast, the lesser effect ofPage 17 of 20
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expression level of the P2X7 receptor in the cancer cells.
At present little is known whether the neoplastic transfor-
mation induces lesser expression of the P2X7-receptor, or
whether the neoplastic transformation is triggered prefer-
entially in cells expressing low levels of the receptor. The
former possibility is supported by data in endometrial
and bladder cells where low expression of the P2X7 recep-
tor was found already in pre-cancerous and early cancer-
ous cells but not in hyperplastic benign cells [38].
Accordingly, the carcinogenic process could have induced
lesser expression of the P2X7 already at early stages of can-
cer development. On the other hand the possibility that
the neoplastic transformation is triggered preferentially in
cells expressing low levels of the receptor is supported by
data as well, and it could be more fundamental to the
understanding of epithelial-cell carcinogenesis. Thus, in
uterine cervical epithelia low expression of the P2X7 recep-
tor was found already in dysplastic cells [9]. Since only a
small fraction of cervical dysplasia cases progresses to can-
cer [44-46], it is possible that low expression of the P2X7
receptor in the cervix precedes the neoplastic transforma-
tion. Accordingly, abrogation of P2X7-mediated apoptosis
could be responsible for the preservation of genetically
aberrant cells that are susceptible to carcinogenic stimuli,
favoring neoplastic transformation [47].
The present data showed only partial inhibition (by about
50%) of papilloma and cancer formation in BzATP-
treated mice. The experiments used the relatively low dose
of 1 μg/cm2 BzATP, based on the 100 μM concentration
used in experiments with cultured cells. The study was not
designed to test higher doses and different frequencies of
drug administration, and it is possible that higher doses
and/or more frequent applications could produce greater
inhibition papillomas and cancers. Additional studies are
needed to test this possibility.
In addition to improving our understanding of the bio-
genesis of skin cancers and possibly other types of epithe-
lial cancers where the P2X7 controls cell growth, the
present results provide a basis for continued research of
novel chemotherapeutic growth-preventive modalities
through regulation of apoptosis. The rationale is that epi-
thelial cancers usually develop from premalignant
lesions, e.g. papilloma, and the cancer risk of premalig-
nant epithelial lesions may vary from 0.1% to 20% [48-
50]. The present results in the mouse model showed that
local treatment with P2X7-receptor agonists could inhibit
the development of papillomas and inhibit the transfor-
mation of papillomas into cancers. BzATP appears to be a
candidate chemotherapeutic growth-preventive drug for
skin papillomas, with an apparent low risk profile of
adverse events when administered locally on the skin.
However, more studies are needed to test whether BzATP
could be used in humans.
Conclusion
• P2X7-dependent apoptosis is an important mecha-
nism that controls the development and progression
of epidermal neoplasia in the mouse.
• P2X7-dependent apoptosis in keratinocytes is medi-
ated by calcium influx via P2X7 pores, and involves the
caspase-9 (mitochondrial) pathway.
• The diminished pro-apoptotic effect of BzATP in
mouse cancer keratinocytes is possibly the result of
low expression of the P2X7 receptor.
• Activation of P2X7-dependent apoptosis, e.g. with
BzATP could be a novel chemotherapeutic growth-pre-
ventive modality for papillomas and epithelial cancers
in vivo.
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